Swedish Orphan Biovitrum AB

SOBI

Equity

ISIN SE0000872095 / Valor 2676862

NASDAQ Nordic Exchange Stockholm, Equities (2025-11-21)

SEK 333.60+0.36%

Swedish Orphan Biovitrum AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company focused on developing and commercializing innovative therapies for rare and serious diseases. Sobi specializes in areas such as hematology, immunology, and gene therapy, addressing unmet medical needs in conditions like hemophilia, immune deficiencies, and other rare disorders. The company operates internationally, leveraging its expertise in biotechnology to bring effective treatments to patients worldwide. Sobi collaborates with healthcare professionals, research institutions, and industry partners to advance its drug pipeline and expand access to its medications, aiming to improve patient outcomes and enhance quality of life for those affected by debilitating diseases.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Growth

For the nine months, sales reached SEK 20,417 million, up from SEK 18,592 million a year ago, demonstrating a strong increase in revenue.

Net Loss

The company reported a net loss of SEK 1,384 million for the nine months, in contrast to a net income of SEK 2,488 million during the same period last year.

Summarized from source with an LLMView Source

Key figures

14.8%1Y

60.2%3Y

124%5Y

Performance

30.3%1Y

29.3%3Y

33.2%5Y

Volatility